July 23 (Reuters) - Quest Diagnostics on Thursday raised its full-year profit forecast, after demand for routine diagnostic ...

Quest Diagnostics, the world’s leading provider of diagnostic information services, said demand for COVID-19 tests “continues ...

Quest Diagnostics shows Q2 earnings beat, upgraded FY guidance, and continued market momentum. Check out why DGX stock is a ...

Nearly half of U.S. employers have dropped marijuana testing for some job applicants, even as workplace drug tests show ...

Quest Diagnostics (NYSE:DGX) reported second-quarter financial results on Thursday. The transcript from the company's ...

Quest Diagnostics raised its full-year outlook after profit and sales rose in the second quarter. The diagnostic testing company on Thursday posted a profit of $320 million, or $2.84 a share, in the ...

Today (the 23rd) at CEDEC 2026, Capcom presented a session on the industry-trending topic of AI in game development, using ...

Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced it is integrating its Haystack MRD® ctDNA test and Comprehensive Genomic Profiling services for ...

Quest Diagnostics crushed Q2 earnings with a 10.5% EPS beat fueled by a 13.1% surge in testing volume, lifting the company's full-year guidance on broad momentum in Alzheimer's blood tests and ...

Advanced diagnostics in brain health, cardiometabolic, and oncology grew by double digits, reflecting a multi-biomarker ...

Neither Old Trafford nor Headingley will host a men's Ashes Test between England and Australia next summer.